¼¼°èÀÇ ¾Ç¼º ½Å°æ±³Á¾ Ä¡·áÁ¦ ½ÃÀå
Malignant Glioma Therapeutics
»óǰÄÚµå : 1775000
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 383 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,239,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,719,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°è ¾Ç¼º ½Å°æ±³Á¾ Ä¡·áÁ¦ ½ÃÀåÀº 2030³â±îÁö 29¾ï ´Þ·¯¿¡ À̸¦ Àü¸Á

2024³â¿¡ 17¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ¾Ç¼º ½Å°æ±³Á¾ Ä¡·áÁ¦ ¼¼°è ½ÃÀåÀº 2024-2030³â°£ CAGR 9.6%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 29¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. º» º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ ´ÙÇü¼º ±³¸ð¼¼Æ÷Á¾ ¼ö¼úÀº CAGR 11.3%¸¦ ³ªÅ¸³»°í, ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 9¾ï 2,620¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ´ÙÇü¼º ±³¸ð¼¼Æ÷Á¾ ¹æ»ç¼± ¿ä¹ý ºÐ¾ßÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£Áß CAGR 7.1%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 4¾ï 5,020¸¸ ´Þ·¯, Áß±¹Àº CAGR 13.4%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ¾Ç¼º ½Å°æ±³Á¾ Ä¡·áÁ¦ ½ÃÀåÀº 2024³â¿¡ 4¾ï 5,020¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 5¾ï 9,160¸¸ ´Þ·¯ ±Ô¸ð¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGRÀº 13.4%·Î ÃßÁ¤µË´Ï´Ù. ±âŸ ÁÖ¸ñÇØ¾ß ÇÒ Áö¿ªº° ½ÃÀåÀ¸·Î¼­´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£Áß CAGRÀº °¢°¢ 6.7%¿Í 8.6%¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR ¾à 7.6%·Î ¼ºÀåÇÒ Àü¸ÁÀÔ´Ï´Ù.

¼¼°èÀÇ ¾Ç¼º ½Å°æ±³Á¾ Ä¡·áÁ¦ ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

¾Ç¼º ½Å°æ±³Á¾ Ä¡·áÁ¦ÀÇ Á߿伺ÀÌ Ä¿Áö´Â ÀÌÀ¯

´ÙÇü¼º ±³¸ð¼¼Æ÷Á¾(GBM), ¼º»ó¼¼Æ÷Á¾, Èñ¼Òµ¹±â¾Æ±³Á¾°ú °°Àº ¾Ç¼º ½Å°æ±³Á¾Àº °¡Àå °ø°ÝÀûÀ̰í Ä¡·á ÀúÇ×¼ºÀÌ ³ôÀº ³úÁ¾¾ç Áß ÇϳªÀÔ´Ï´Ù. Á¦ÇÑµÈ »ýÁ¸À², Àç¹ß À§Çè ¹× °³¼±µÈ Ä¡·á Àü·«ÀÇ Çʿ伺À¸·Î ÀÎÇØ ½Å°æ±³Á¾ Ä¡·á¸¦ À§ÇÑ »õ·Î¿î ¾à¹°, Á¤¹ÐÀÇ·á ¹× ¸é¿ª¿ä¹ý ±â¹Ý ¼Ö·ç¼ÇÀ» °³¹ßÇϱâ À§ÇÑ ¿¬±¸ ³ë·ÂÀÌ ÁøÇàµÇ°í ÀÖ½À´Ï´Ù.

Ç¥ÀûÄ¡·á, À¯ÀüÀÚÄ¡·á, Á¾¾ç¿ëÇØ ¹ÙÀÌ·¯½º Ä¡·áÀÇ ¹ßÀüÀ¸·Î ȯÀÚÀÇ »ýÁ¸À²À» ³ôÀÌ°í »îÀÇ ÁúÀ» Çâ»ó½Ãų ¼ö ÀÖ´Â »õ·Î¿î Ä¡·á¹ýÀÌ µîÀåÇϰí ÀÖ½À´Ï´Ù. ½Å°æÁ¾¾çÇÐ ¿¬±¸¿¡ ´ëÇÑ Á¤ºÎ ÀÌ´Ï¼ÅÆ¼ºê, ¹Î°£ ÅõÀÚ ¹× ÇмúÀû Çù·ÂÀº ½Å¾à °³¹ß ÆÄÀÌÇÁ¶óÀÎÀ» °¡¼ÓÈ­Çϰí ÀÖ½À´Ï´Ù.

Çõ½ÅÀº ¾î¶»°Ô ¾Ç¼º ½Å°æ±³Á¾ Ä¡·áÁ¦ÀÇ ¼º´ÉÀ» Çâ»ó½Ã۴°¡?

AI¿Í CRISPR À¯ÀüÀÚ ÆíÁý ±â¼ú, °³ÀÎ ¸ÂÃãÇü Á¾¾ç ÇÁ·ÎÆÄÀϸµÀº ½Å°æ±³Á¾ Ä¡·á¿¡ Çõ¸íÀ» ÀÏÀ¸Å°°í ÀÖÀ¸¸ç, CAR-T ¼¼Æ÷ Ä¡·á¿Í ¸é¿ª°ü¹®¾ïÁ¦Á¦´Â ÀÓ»ó½ÃÇè¿¡¼­ À¯¸ÁÇÑ °á°ú¸¦ º¸¿© °Ç°­ÇÑ ³ú Á¶Á÷ ¼Õ»óÀ» ÃÖ¼ÒÈ­Çϴ ǥÀû Á¢±Ù¹ýÀ» Á¦°øÇÕ´Ï´Ù. Á¦°øÇÕ´Ï´Ù.

¶ÇÇÑ, ÀüÀÚ±âÆÄ¸¦ ÀÌ¿ëÇÏ¿© ¾Ï¼¼Æ÷ÀÇ ºÐ¿­À» ¾ïÁ¦ÇÏ´Â Çõ½ÅÀûÀÎ Ä¡·á¹ýÀÎ Á¾¾çÄ¡·áÇʵå(TTFields)´Â È­Çпä¹ýÀ̳ª ¹æ»ç¼± ¿ä¹ýÀ» º¸¿ÏÇÏ´Â Ä¡·á¹ýÀ¸·Î ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎÀ» ¹Þ°í ÀÖ½À´Ï´Ù. ³ª³ë±â¼úÀ» Ȱ¿ëÇÑ Ç÷¾×³úÀ庮 Åõ°ú ±â¼úµµ ¾à¹° Àü´Þ È¿À²À» Çâ»ó½ÃÄÑ º¸´Ù È¿°úÀûÀÎ ½Å°æ±³Á¾ Ä¡·á¸¦ °¡´ÉÇÏ°Ô Çϰí ÀÖ½À´Ï´Ù.

ÁÖ¿ä ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎÀº ¹«¾ùÀΰ¡?

¾Ç¼º ½Å°æ±³Á¾ ¹ß»ý·ü Áõ°¡, ¿¬±¸ ÅõÀÚ Áõ°¡, Á¤¹Ð Á¾¾çÇÐÀÇ ¹ßÀüÀÌ ½ÃÀå È®´ëÀÇ ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù. ±³¸ð¼¼Æ÷Á¾ ȯÀÚÀÇ ¿¹Èĸ¦ °³¼±ÇÒ ¼ö ÀÖ´Â Ä¡·á¹ýÀÇ ½Ã±ÞÇÑ Çʿ伺ÀÌ »ý¸í°øÇÐ ±â¾÷ ¹× Á¦¾àȸ»ç¿¡ Â÷¼¼´ë Ä¡·á¹ý °³¹ßÀ» Ã˱¸Çϰí ÀÖ½À´Ï´Ù.

FDA ¹× EMA¿Í °°Àº ±ÔÁ¦ ±â°üÀº Çõ½ÅÀûÀÎ ½Å°æ±³Á¾ Ä¡·áÁ¦¿¡ ÆÐ½ºÆ®Æ®·¢ ÁöÁ¤ ¹× Èñ±ÍÁúȯ Ä¡·áÁ¦ ½ÂÀÎÀ» ºÎ¿©ÇÏ¿© À¯¸ÁÇÑ ¾à¹° ½ÃÀå ÁøÀÔÀ» °¡¼ÓÈ­Çϰí ÀÖ½À´Ï´Ù. ÀÓ»ó½ÃÇè ³×Æ®¿öÅ©¿Í ȯÀÚ Áß½ÉÀÇ ¿¬±¸ ÀÚ±ÝÀÇ È®´ëµµ »õ·Î¿î ½Å°æ±³¸ð¼¼Æ÷Á¾ Ä¡·áÁ¦ÀÇ ÆÄÀÌÇÁ¶óÀÎÀ» °­È­Çϰí ÀÖ½À´Ï´Ù.

¶ÇÇÑ, ½Å°æ±³Á¾ Á¶±â ¹ß°ß ¹× Ä¡·á °èȹ¿¡¼­ AI¸¦ Ȱ¿ëÇÑ Áø´ÜÀÇ ¿ªÇÒÀÌ Áõ°¡ÇÔ¿¡ µû¶ó Ä¡·á ¼ºÀûÀÌ Çâ»óµÇ°í ÀÖ½À´Ï´Ù. ¸é¿ª¿ä¹ý, ¹æ»ç¼± ¿ä¹ý, °íÁ¤¹Ð ¾à¹° Àü´ÞÀÇ Á¶ÇÕÀ» Æ÷ÇÔÇÑ ´ÙÁß ¸ð´Þ Ä¡·á Á¢±Ù¹ýÀÇ ÅëÇÕÀº ½Å°æ±³Á¾ Ä¡·áÀÇ È¹±âÀûÀÎ ¹ßÀüÀ» ÃËÁøÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¾î¶² °úÁ¦¿Í ¹Ì·¡ ±âȸ°¡ Á¸ÀçÇÒ±î?

³ôÀº Ä¡·áºñ, ¾àÁ¦ ³»¼º, Ä¡·á¹ý °³¹ßÀ» ¾î·Æ°Ô ÇÏ´Â ½Å°æ±³Á¾ÀÇ º¹ÀâÇÑ Æ¯¼º µîÀÌ ¹®Á¦Á¡À¸·Î ÁöÀûµÇ°í ÀÖ½À´Ï´Ù. Ç÷¾×³úÀ庮Àº ¿©ÀüÈ÷ Å« Àå¾Ö¹°À̸ç, ¸¹Àº ¾à¹°ÀÇ È¿´ÉÀ» Á¦ÇÑÇϰí ÀÖ½À´Ï´Ù. ±×·¯³ª »õ·Î¿î ³ª³ë±â¼ú ±â¹ÝÀÇ ¾à¹° Àü´Þ ½Ã½ºÅÛ, AI ±â¹Ý Á¤¹Ð Á¾¾çÇÐ, ȹ±âÀûÀÎ ¸é¿ª¿ä¹ýÀº º¸´Ù È¿°úÀûÀÌ°í °³ÀÎÈ­µÈ ½Å°æ±³Á¾ Ä¡·áÀÇ ±âȸ¸¦ Á¦°øÇÕ´Ï´Ù. ºñħ½ÀÀû Á¶±â ¹ß°ß µµ±¸¿Í AI ±â¹Ý ÀÓ»ó ÀÇ»ç°áÁ¤À¸·ÎÀÇ È®ÀåÀº ½ÃÀåÀ» ´õ¿í Çõ½ÅÀûÀ¸·Î º¯È­½Ãų ¼ö ÀÖ½À´Ï´Ù.

ºÎ¹®

Ä¡·á(´ÙÇü¼º ±³¸ð¼¼Æ÷Á¾ ¼ö¼ú, ´ÙÇü¼º ±³¸ð¼¼Æ÷Á¾ ¹æ»ç¼± ¿ä¹ý, ´ÙÇü¼º ±³¸ð¼¼Æ÷Á¾ È­Çпä¹ý, ´ÙÇü¼º ±³¸ð¼¼Æ÷Á¾ Ç¥ÀûÄ¡·á, ´ÙÇü¼º ±³¸ð¼¼Æ÷Á¾ Á¾¾ç Ä¡·á ¿µ¿ª ¿ä¹ý, ´ÙÇü¼º ±³¸ð¼¼Æ÷Á¾ ¸é¿ªÄ¡·á), ¾àÁ¦(Temozolomide Drug, Bevacizumab Drug, Lomustine Drug, Carmustine Wafers Drug, Other Glioblastoma Multiforme Drugs), ÃÖÁ¾»ç¿ëÀÚ(º´¿ø ÃÖÁ¾»ç¿ëÀÚ, Ŭ¸®´Ð ÃÖÁ¾»ç¿ëÀÚ, ¿Ü·¡¼ö¼ú¼¾ÅÍ(ASC) ÃÖÁ¾»ç¿ëÀÚ)

Á¶»ç ´ë»ó ±â¾÷ ¿¹

AI ÅëÇÕ

´ç»ç´Â À¯È¿ÇÑ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AIÅø¿¡ ÀÇÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ º¯ÇõÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â ÀϹÝÀûÀÎ LLM³ª ¾÷°èº° SLM Äõ¸®¿¡ µû¸£´Â ´ë½Å¿¡, ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ´ë·® ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî, Àü ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»çÀÇ ±¹°¡, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±â¹ÝÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¼öÀÍ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº °¨¼Ò, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû ¹× °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Malignant Glioma Therapeutics Market to Reach US$2.9 Billion by 2030

The global market for Malignant Glioma Therapeutics estimated at US$1.7 Billion in the year 2024, is expected to reach US$2.9 Billion by 2030, growing at a CAGR of 9.6% over the analysis period 2024-2030. Glioblastoma Multiforme Surgery, one of the segments analyzed in the report, is expected to record a 11.3% CAGR and reach US$926.2 Million by the end of the analysis period. Growth in the Glioblastoma Multiforme Radiation Therapy segment is estimated at 7.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$450.2 Million While China is Forecast to Grow at 13.4% CAGR

The Malignant Glioma Therapeutics market in the U.S. is estimated at US$450.2 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$591.6 Million by the year 2030 trailing a CAGR of 13.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 6.7% and 8.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 7.6% CAGR.

Global Malignant Glioma Therapeutics Market - Key Trends & Drivers Summarized

Why Is Malignant Glioma Therapeutics Gaining Importance?

Malignant gliomas, including glioblastoma multiforme (GBM), astrocytomas, and oligodendrogliomas, are some of the most aggressive and treatment-resistant brain tumors. Limited survival rates, recurrence risks, and the need for improved therapeutic strategies are pushing research efforts to develop novel drugs, precision medicine, and immunotherapy-based solutions for glioma treatment.

With advancements in targeted therapy, gene therapy, and oncolytic virus therapy, new treatment approaches are emerging that could extend patient survival rates and enhance quality of life. Government initiatives, private investments, and academic collaborations in neuro-oncology research are accelerating drug development pipelines.

How Are Innovations Enhancing the Performance of Malignant Glioma Therapeutics?

The integration of AI in drug discovery, CRISPR gene-editing technology, and personalized tumor profiling is revolutionizing glioma treatment. CAR-T cell therapy and immune checkpoint inhibitors are demonstrating promising results in clinical trials, offering targeted approaches that minimize damage to healthy brain tissue.

Additionally, tumor-treating fields (TTFields), an innovative therapy that disrupts cancer cell division using electromagnetic waves, is gaining regulatory approval as a complementary treatment to chemotherapy and radiation therapy. Nanotechnology-driven blood-brain barrier penetration techniques are also improving drug delivery efficiency, enabling more effective glioma treatments.

What Are the Key Market Drivers?

The rising incidence of malignant gliomas, increasing research investments, and advancements in precision oncology are driving market expansion. The urgent need for therapies that improve prognosis for glioblastoma patients is encouraging biotech firms and pharmaceutical companies to develop next-generation treatment modalities.

Regulatory bodies such as the FDA and EMA are granting fast-track designations and orphan drug approvals to innovative glioma therapies, accelerating market entry for promising drugs. The expansion of clinical trial networks and patient-centric research funding is also enhancing the pipeline for new glioblastoma treatments.

Additionally, the increasing role of AI-powered diagnostics in early glioma detection and treatment planning is improving therapeutic outcomes. The integration of multi-modal treatment approaches, including a combination of immunotherapy, radiation, and precision drug delivery, is expected to drive significant advancements in glioma care.

What Challenges and Future Opportunities Exist?

Challenges include high treatment costs, drug resistance, and the complex nature of gliomas, making therapeutic development difficult. The blood-brain barrier remains a significant hurdle, limiting the effectiveness of many drugs. However, emerging nanotechnology-based drug delivery systems, AI-assisted precision oncology, and breakthrough immunotherapies present opportunities for more effective and personalized glioma treatments. Expansion into non-invasive early detection tools and AI-driven clinical decision-making could further transform the market.

SCOPE OF STUDY:

The report analyzes the Malignant Glioma Therapeutics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Treatment (Glioblastoma Multiforme Surgery, Glioblastoma Multiforme Radiation Therapy, Glioblastoma Multiforme Chemotherapy, Glioblastoma Multiforme Targeted Therapy, Glioblastoma Multiforme Tumor Treating Field Therapy, Glioblastoma Multiforme Immunotherapy); Drug (Temozolomide Drug, Bevacizumab Drug, Lomustine Drug, Carmustine Wafers Drug, Other Glioblastoma Multiforme Drugs); End-Use (Hospitals End-Use, Clinics End-Use, Ambulatory Surgery Centers End-Use)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 35 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â